10.99
0.02 (0.18%)
| Previous Close | 10.97 |
| Open | 11.03 |
| Volume | 3,307,159 |
| Avg. Volume (3M) | 6,456,185 |
| Market Cap | 7,471,068,160 |
| Price / Sales | 284.39 |
| Price / Book | 1.65 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Operating Margin (TTM) | -4,823.84% |
| Diluted EPS (TTM) | -0.750 |
| Quarterly Revenue Growth (YOY) | -16.10% |
| Quarterly Earnings Growth (YOY) | -96.70% |
| Total Debt/Equity (MRQ) | 1.93% |
| Current Ratio (MRQ) | 33.47 |
| Operating Cash Flow (TTM) | -839.45 M |
| Levered Free Cash Flow (TTM) | -375.20 M |
| Return on Assets (TTM) | -10.73% |
| Return on Equity (TTM) | -12.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Roivant Sciences Ltd. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -2.5 |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.10 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 30.68% |
| % Held by Institutions | 83.50% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Qvt Financial Lp | 31 Mar 2025 | 65,793,779 |
| Sb Investment Advisers (Uk) Ltd | 31 Mar 2025 | 61,852,718 |
| Patient Square Capital Lp | 31 Mar 2025 | 12,480,000 |
| 52 Weeks Range | ||
| Median | 18.00 (63.79%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 18 Jun 2025 | 18.00 (63.79%) | Buy | 11.44 |
| 28 May 2025 | 18.00 (63.79%) | Buy | 10.62 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GOLD DANIEL ALLEN | - | 11.40 | -36,756,758 | -419,027,041 |
| MANCHESTER KEITH S | - | 11.40 | -17,389,525 | -198,240,585 |
| PULIK RICHARD | - | 11.39 | -1,653 | -18,828 |
| QVT FINANCIAL LP | - | 11.40 | -36,756,758 | -419,027,041 |
| Aggregate Net Quantity | -90,904,694 | |||
| Aggregate Net Value ($) | -1,036,313,495 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 11.40 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PULIK RICHARD | Officer | 28 Jun 2025 | Disposed (-) | 1,653 | 11.39 | 18,828 |
| QVT FINANCIAL LP | 25 Jun 2025 | Disposed (-) | 36,756,758 | 11.40 | 419,027,041 | |
| MANCHESTER KEITH S | Director | 25 Jun 2025 | Disposed (-) | 17,389,525 | 11.40 | 198,240,585 |
| GOLD DANIEL ALLEN | Director | 25 Jun 2025 | Disposed (-) | 36,756,758 | 11.40 | 419,027,041 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |